Rondo Therapeutics is developing a next-generation immuno-oncology platform aimed at treating solid tumors, centered on bispecific antibody candidates. The company leverages a proprietary immuno-stimulatory platform and founders’ deep expertise in bispecific antibody discovery. Its lead candidates are preclinical and being advanced toward initial Phase 1 clinical studies. Rondo positions its approach to overcome challenges that have limited T‑cell engagers and other bispecifics in solid tumors despite successes in hematologic cancers. The company recently closed an oversubscribed financing to support pipeline development. The proceeds will fund continued development of its preclinical pipeline and progression of lead assets toward clinical entry.

Total raised

$67M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2022